Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC
Introduction: This study aims to report our 13-year institutional experience with single-fraction stereotactic body radiation therapy (SF-SBRT) for early stage NSCLC. Methods: A single-institutional retrospective review of patients with biopsy-proven peripheral cT1-2N0M0 NSCLC undergoing definitive...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364323001418 |
| _version_ | 1797383667054542848 |
|---|---|
| author | Austin J. Iovoli, MD Sharan Prasad, BSc Sung Jun Ma, MD Fatemeh Fekrmandi, MD, MSc Nadia K. Malik, MD Simon Fung-Kee-Fung, MD Mark K. Farrugia, MD, PhD Anurag K. Singh, MD |
| author_facet | Austin J. Iovoli, MD Sharan Prasad, BSc Sung Jun Ma, MD Fatemeh Fekrmandi, MD, MSc Nadia K. Malik, MD Simon Fung-Kee-Fung, MD Mark K. Farrugia, MD, PhD Anurag K. Singh, MD |
| author_sort | Austin J. Iovoli, MD |
| collection | DOAJ |
| description | Introduction: This study aims to report our 13-year institutional experience with single-fraction stereotactic body radiation therapy (SF-SBRT) for early stage NSCLC. Methods: A single-institutional retrospective review of patients with biopsy-proven peripheral cT1-2N0M0 NSCLC undergoing definitive SF-SBRT between September 2008 and May 2022 was performed. All patients were treated to 27 Gy with heterogeneity corrections or 30 Gy without. Primary outcomes were overall survival and progression-free survival. Secondary outcomes included local failure, nodal failure, distant failure, and second primary lung cancer. Results: Among 263 eligible patients, the median age was 76 years (interquartile range [IQR]: 70–81 y) and median follow-up time was 27.2 months (IQR: 14.25–44.9 mo). Median tumor size was 1.9 cm (IQR: 1.4–2.6 cm), and 224 (85%) tumors were T1. There were 92 patients (35%) alive at the time of analysis with a median follow-up of 34.0 months (IQR: 16.6–50.0 mo). Two- and five-year overall survival was 65% and 26%, respectively. A total of 74 patients (28%) developed disease progression. Rates of five-year local failure, nodal failure, distant failure, and second primary lung cancer were 12.7%, 14.7%, 23.5%, and 12.0%, respectively. Conclusions: Consistent with multiple prospective randomized trials, in a large real-world retrospective cohort, SF-SBRT for peripheral early stage NSCLC was an effective treatment approach. |
| first_indexed | 2024-03-08T21:24:21Z |
| format | Article |
| id | doaj.art-88917c3e42c941abb7cae98f65dd8bbf |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-03-08T21:24:21Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-88917c3e42c941abb7cae98f65dd8bbf2023-12-21T07:37:25ZengElsevierJTO Clinical and Research Reports2666-36432023-12-01412100598Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLCAustin J. Iovoli, MD0Sharan Prasad, BSc1Sung Jun Ma, MD2Fatemeh Fekrmandi, MD, MSc3Nadia K. Malik, MD4Simon Fung-Kee-Fung, MD5Mark K. Farrugia, MD, PhD6Anurag K. Singh, MD7Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New YorkJacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New YorkDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New YorkDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New YorkDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New YorkDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New YorkDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New YorkDepartment of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York; Corresponding author. Address for correspondence: Anurag K. Singh, MD, Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm Street, Buffalo, NY 14203.Introduction: This study aims to report our 13-year institutional experience with single-fraction stereotactic body radiation therapy (SF-SBRT) for early stage NSCLC. Methods: A single-institutional retrospective review of patients with biopsy-proven peripheral cT1-2N0M0 NSCLC undergoing definitive SF-SBRT between September 2008 and May 2022 was performed. All patients were treated to 27 Gy with heterogeneity corrections or 30 Gy without. Primary outcomes were overall survival and progression-free survival. Secondary outcomes included local failure, nodal failure, distant failure, and second primary lung cancer. Results: Among 263 eligible patients, the median age was 76 years (interquartile range [IQR]: 70–81 y) and median follow-up time was 27.2 months (IQR: 14.25–44.9 mo). Median tumor size was 1.9 cm (IQR: 1.4–2.6 cm), and 224 (85%) tumors were T1. There were 92 patients (35%) alive at the time of analysis with a median follow-up of 34.0 months (IQR: 16.6–50.0 mo). Two- and five-year overall survival was 65% and 26%, respectively. A total of 74 patients (28%) developed disease progression. Rates of five-year local failure, nodal failure, distant failure, and second primary lung cancer were 12.7%, 14.7%, 23.5%, and 12.0%, respectively. Conclusions: Consistent with multiple prospective randomized trials, in a large real-world retrospective cohort, SF-SBRT for peripheral early stage NSCLC was an effective treatment approach.http://www.sciencedirect.com/science/article/pii/S2666364323001418Lung cancerNSCLCSBRTRadiationRadiosurgery |
| spellingShingle | Austin J. Iovoli, MD Sharan Prasad, BSc Sung Jun Ma, MD Fatemeh Fekrmandi, MD, MSc Nadia K. Malik, MD Simon Fung-Kee-Fung, MD Mark K. Farrugia, MD, PhD Anurag K. Singh, MD Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC JTO Clinical and Research Reports Lung cancer NSCLC SBRT Radiation Radiosurgery |
| title | Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC |
| title_full | Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC |
| title_fullStr | Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC |
| title_full_unstemmed | Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC |
| title_short | Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC |
| title_sort | long term survival and failure outcomes of single fraction stereotactic body radiation therapy in early stage nsclc |
| topic | Lung cancer NSCLC SBRT Radiation Radiosurgery |
| url | http://www.sciencedirect.com/science/article/pii/S2666364323001418 |
| work_keys_str_mv | AT austinjiovolimd longtermsurvivalandfailureoutcomesofsinglefractionstereotacticbodyradiationtherapyinearlystagensclc AT sharanprasadbsc longtermsurvivalandfailureoutcomesofsinglefractionstereotacticbodyradiationtherapyinearlystagensclc AT sungjunmamd longtermsurvivalandfailureoutcomesofsinglefractionstereotacticbodyradiationtherapyinearlystagensclc AT fatemehfekrmandimdmsc longtermsurvivalandfailureoutcomesofsinglefractionstereotacticbodyradiationtherapyinearlystagensclc AT nadiakmalikmd longtermsurvivalandfailureoutcomesofsinglefractionstereotacticbodyradiationtherapyinearlystagensclc AT simonfungkeefungmd longtermsurvivalandfailureoutcomesofsinglefractionstereotacticbodyradiationtherapyinearlystagensclc AT markkfarrugiamdphd longtermsurvivalandfailureoutcomesofsinglefractionstereotacticbodyradiationtherapyinearlystagensclc AT anuragksinghmd longtermsurvivalandfailureoutcomesofsinglefractionstereotacticbodyradiationtherapyinearlystagensclc |